Ensign Peak Advisors
KLRS

Ensign Peak Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Ensign Peak Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-317
Closed -$58K – 2255
2022
Q3 		$58K Buy
317
+67
+27% +$10.4K ﹤0.01% 2196
2022
Q2 		$22K Hold
250
– – ﹤0.01% 2124
2022
Q1 		$39K Hold
250
– – ﹤0.01% 2149
2021
Q4 		$74K Buy
+250
New +$116K ﹤0.01% 2107

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Ensign Peak Advisors's KLRS Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Kalaris Therapeutics (KLRS) in Q4 2022, closing a stake of 317 shares — an estimated $58K sold.

Ensign Peak Advisors first reported a position in KLRS in Q4 2021 and held it in 4 quarters. The position peaked at $74K in Q4 2021. 85 funds tracked by Wall St. Rank hold KLRS as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Kalaris Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 317 Kalaris Therapeutics shares in Q4 2022, an estimated $58K.
  • Ensign Peak Advisors first reported a position in Kalaris Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Kalaris Therapeutics position peaked at $74K in Q4 2021.
  • 85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.